









市场行情
/
股票
/
nasdaq-alms
/

Alumis Inc

ALMS

11.400USD

-0.050-0.44%

收盘 12/24, 13:00（美东）报价延迟15分钟

1.19B总市值

亏损市盈率 TTM



Alumis Inc

11.400

-0.050-0.44%

概览公司财务分析

概览

公司

财务

分析

关于 Alumis Inc 公司

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Alumis Inc简介



公司代码ALMS

公司名称Alumis Inc

上市日期Jun 28, 2024

CEOBabler (Martin)

员工数量168

证券类型Ordinary Share

年结日Jun 28

公司地址280 East Grand Avenue

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话16502316625

网址https://www.alumis.com/

公司代码ALMS

上市日期Jun 28, 2024

CEOBabler (Martin)

Alumis Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Martin Babler

Chairman of the Board, President, Chief Executive Officer

106.45K

Mr. Mark Bradley

Chief Development Officer

48.73K

+121.71%

Mr. Derrick Richardson

Senior Vice President - People and Culture

42.80K

Mr. John R. Schroer

Chief Financial Officer

28.00K

Dr. Jorn Drappa, M.D., Ph.D.

Chief Medical Officer, Head - Research and Development

25.45K

Mr. Patrick (Pat) Machado, J.D.

Independent Director

7.06K

Ms. Lynn A. Tetrault, J.D.

Independent Director

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

Mr. Roy C. Hardiman, J.D.

Chief Business and Strategy Officer

Mr. Alan B. Colowick, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Martin Babler

Chairman of the Board, President, Chief Executive Officer

106.45K

Mr. Mark Bradley

Chief Development Officer

48.73K

+121.71%

Mr. Derrick Richardson

Senior Vice President - People and Culture

42.80K

Mr. John R. Schroer

Chief Financial Officer

28.00K

Dr. Jorn Drappa, M.D., Ph.D.

Chief Medical Officer, Head - Research and Development

25.45K

Mr. Patrick (Pat) Machado, J.D.

Independent Director

7.06K

收入明细

FY2025Q2

FY2025Q1

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

2.67M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Ayur Maya Capital Management Company, L.P.

15.57%

Foresite Capital Management, LLC

10.91%

Samsara BioCapital, LLC

5.28%

VenBio Partners LLC

4.75%

The Vanguard Group, Inc.

4.15%

其他

59.33%

持股股东

占比

Ayur Maya Capital Management Company, L.P.

15.57%

Foresite Capital Management, LLC

10.91%

Samsara BioCapital, LLC

5.28%

VenBio Partners LLC

4.75%

The Vanguard Group, Inc.

4.15%

其他

59.33%

股东类型

持股股东

占比

Private Equity

34.56%

Investment Advisor

16.00%

Hedge Fund

11.90%

Investment Advisor/Hedge Fund

9.71%

Venture Capital

8.00%

Research Firm

0.84%

Individual Investor

0.82%

Bank and Trust

0.34%

Pension Fund

0.04%

其他

17.79%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

211

79.11M

81.97%

+900.81K

2025Q3

210

78.21M

82.24%

-347.38K

2025Q2

186

78.54M

55.16%

+26.45M

2025Q1

129

40.48M

86.71%

-471.52K

2024Q4

110

40.33M

76.60%

+5.09M

2024Q3

35.23M

67.43%

+3.39M

2024Q2

30.28M

0.00%

+30.28M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Ayur Maya Capital Management Company, L.P.

15.14M

15.63%

Jun 30, 2025

Foresite Capital Management, LLC

10.03M

10.35%

-5.17M

-34.02%

Jun 30, 2025

Samsara BioCapital, LLC

4.80M

4.96%

Jun 30, 2025

VenBio Partners LLC

4.62M

4.77%

+1.83M

+65.74%

Jun 30, 2025

The Vanguard Group, Inc.

3.40M

3.51%

+2.47M

+263.23%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.81M

3.93%

+2.46M

+182.05%

Jun 30, 2025

Trium Capital LLP

2.65M

2.73%

+2.65M

Jun 30, 2025

Nextech Invest, Ltd.

2.92M

3.01%

+1.44M

+97.43%

Jun 30, 2025

Cormorant Asset Management, LP

2.15M

2.22%

Jun 30, 2025

SR One Capital Management, LP

1.96M

2.02%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ProShares Ultra Nasdaq Biotechnology

0.09%

iShares Micro-Cap ETF

0.05%

Invesco Nasdaq Biotechnology ETF

0.05%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Value ETF

0.03%

Invesco RAFI US 1500 Small-Mid ETF

0.03%

ProShares Hedge Replication ETF

0.02%

iShares Russell 2000 ETF

0.01%

ProShares UltraPro Russell2000

0.01%

Proshares Ultra Russell 2000

0.01%

ProShares Ultra Nasdaq Biotechnology

占比0.09%

iShares Micro-Cap ETF

占比0.05%

Invesco Nasdaq Biotechnology ETF

占比0.05%

iShares Biotechnology ETF

占比0.03%

iShares Russell 2000 Value ETF

占比0.03%

Invesco RAFI US 1500 Small-Mid ETF

占比0.03%

ProShares Hedge Replication ETF

占比0.02%

iShares Russell 2000 ETF

占比0.01%

ProShares UltraPro Russell2000

占比0.01%

Proshares Ultra Russell 2000

占比0.01%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Alumis Inc的前五大股东是谁？



Alumis Inc 的前五大股东如下：
Ayur Maya Capital Management Company, L.P.持有股份：15.14M，占总股份比例：15.63%。
Foresite Capital Management, LLC持有股份：10.03M，占总股份比例：10.35%。
Samsara BioCapital, LLC持有股份：4.80M，占总股份比例：4.96%。
VenBio Partners LLC持有股份：4.62M，占总股份比例：4.77%。
The Vanguard Group, Inc.持有股份：3.40M，占总股份比例：3.51%。